Consequently, modified viral vectors targeting CD46 currently are being exploited for a wide range of therapeutic applications, such as Ad26 vaccine vectors for treatment of HIV (88) and COVID-19 (89) and for multiple forms of cancer (see below). Here, CD46 is linked to cancer.